Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS)

Clinical Interventions in Aging

Volumn 3, Issue 3, 2008, Pages 581-593

  Guymer, Robyn H ^a,b   Dimitrov, Peter N ^a   Varsamidis, Mary ^a   Lim, Lyndell L ^a,b   Baird, Paul N ^a   Vingrys, Algis J ^a   Robman, Luba ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Age related macular degeneration; HMG Co A reductase inhibitor; Progression; Randomized controlled trial; Statin; Visual function

Indexed keywords

PLACEBO; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HAPLOTYPE; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK REDUCTION; SAMPLE SIZE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VISION TEST; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SIMVASTATIN; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 54949156790     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Alcocer L. 2003. Statins for everybody? New evidence on the efficacy and safety of the inhibitors of HMG Co-A reductase. Am J Ther, 10:423-8.
2. Alvarez de Sotomayor M, Andriantsitohaina R. 2001. Simvastatin and Ca(2+) signaling in endothelial cells: involvement of rho protein. Biochem Biophys Res Commun, 280:486-90.
3. [AREDS] Age-Related Eye Disease Study Research Group. 1999. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials, 20:573-600.
4. [AREDS] Age-Related Eye Disease Study Research Group. 2001. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol, 119:1417-36.
5. Ariyasu R, Lee P, Linton K, et al. 1996. Sensitivity, specificity, and predictive values of screening tests for eye conditions in a clinic-based population. Ophthalmology, 103:1751-60.
6. Bailey I, Lovie J. 1976. New design principles for visual acuity letter charts. Am J Optom Physiol Optics, 53:740-5.
7. Baird P, Richardson A, Robman L, et al. 2006. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat, 27:337-42.
8. Baird PN, Robman, LD, Richardson, AJ, et al. 2008. Gene-enviromnent interaction in progression of AMD - the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet, 17:1299-305.
9. Baker S, Tarnopolsky M. 2005. Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis, 9:E26.
10. Bellosta S, Ferri N, Bernini F, et al. 2000. Non-lipid-related effects of statins. Ann Med, 32:164-76.
11. Bird AC, Bressler NM, Bressler SB, et al. 1995. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol, 39:367-74.
12. Brown B, Adams A, Coletta NJ, et al. 1986. Dark adaptation in age-related maculopathy. Ophthalmic Physiol Optics, 6:81-4.
13. Chuo JY, Wiens M, Etminan M, et al. 2007. Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies. Ophthalmic Epidemiol, 14:367-74.
14. Curcio CA, Medeiros NE, Millican CL. 1996. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci, 37:1236-49.
15. Delcourt C, Michel F, Colvez A, et al. 2001. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol, 8:237-49.
16. Demirel S, Vingrys AJ. 1994. Eye movements during perimetry and the effect that fixational instability has on perimetric outcomes. J Glaucoma, 3:28-35.
17. Dimitrov PN, Guymer RH, Zele AJ, et al. 2008. Measuring rod and cone dynamics in age-related maculopathy. Invest Ophthalmol Vis Sci, 49:55-65.
18. Edwards AO, Ritter R 3rd, Abel KJ, et al. 2005. Complement factor H polymorphism and age-related macular degeneration. Science, 308:421-4.
19. Friedman E, Rigas IK, Makar M. 2005. The relationship of statin use to the development of age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci ARVO, 46:199.
20. Friedman E. 2004. Update of the vascular model of AMD. Br J Ophthalmol, 88:161-3.
21. Gunkel R, Gouras P. 1963. Changes in scotopic visibility threshold with age. Arch Ophthalmol, 69:4-9.
22. Guymer R, Luthert P, Bird A. 1999. Changes in Bruch's membrane and related structures with age. Prog Ret Eye Res, 18:59-90.
23. Hageman GS, Anderson DH, Johnson LV, et al. 2005. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A, 102:7227-32.
24. Hageman GS, Luthert PJ, Victor Chong NH, et al. 2001. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res, 20:705-32.
25. Haimovici R, Gantz DL, Rumelt S, et al. 2001. The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci, 42:1592-9.
26. Haines JL, Hauser MA, Schmidt S, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science, 308:419-21.
27. Hall NF, Gale CR, Syddall H, et al. 2001. Risk of macular degeneration in users of statins: cross sectional study. BMJ, 323:375-6.
28. Hanley JM, Haugen T, Heath E. 1983. Biosynthesis and processing of rat haptoglobin. J Biol Chem, 258:7858-69.
29. Hassell JB, Weih LM, Keeffe JE. 2000. A measure of handicap for low vision rehabilitation: the impact of vision impairment profile. Clin Exp Ophthalmol, 28:156-61.
30. Hess D, Fagan S. 2001. Pharmacology and clinical experience with simvastatin. Expert Opin Pharmacother, 2:153-63.
31. Hunninghake DB, Knopp RH, Schonfeld G, et al. 1990. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis, 85:81-9.
32. Inoue I, Goto S, Mizotani K, et al. 2000. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sciences, 67:863-76.
33. Jialal I, Stein D, Balis D, et al. 2001. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 103:1933-5.
34. Jones P, Kafonek S, Laurora I, et al. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol, 81:582-7.
35. Keeffe J, McCarty C, Hassell J, et al. 1999. Description and measurement of handicap caused by vision impairment. Aust N Z J Ophthalmol, 27:184-6.
36. Klein R, Deng Y, Klein BE, et al. 2007a. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol, 143:473-83.
37. Klein R, Klein BE. 2004. Do statins prevent age-related macular degeneration? Am J Ophthalmol, 137:747-9.
38. Klein R, Klein BE, Tomany SC, et al. 2003a. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology, 110:636-43.
39. Klein R, Klein BE, Tomany SC, et al. 2003b. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol, 121:1151-5.
40. Klein R, Knudtson MD, Klein BE. 2007b. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol, 144:1-6.
41. Klein RJ, Zeiss C, Chew EY, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science, 308:385-9.
42. Kuvin JT, Karas RH. 2003. The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers. Curr Opin Cardiol, 18:295-300.
43. Kwak B, Mulhaupt F, Veillard N, et al. 2001. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly, 131:41-6.
44. Lamb T. 1981. The involvement of rod photoreceptors in dark adaptation. Vision Res, 21:1773-82.
45. Lamb T, Pugh E, Jr. 2004. Dark adaptation and the retinoid cycle of vision. Prog Ret Eye Res, 23:307-80.
46. Lamperti C, Naini A, Lucchini V, et al. 2005. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol, 62:1709-12.
47. Ludvigh E, McCarthy E. 1938. Absorption of the visible light by the refractive media of the human eye. Arch Ophthalmol, 20:37.
48. [MPSG] Macular Photocoagulation Study Group. 1991. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol, 109:1220-31.
49. McCarty CA, Mukesh BN, Fu CL, et al. 2001a. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol, 119:1455-62.
50. McCarty CA, Mukesh BN, Guymer RH, et al. 2001b. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. MJA, 175:17.
51. McGwin G Jr, Modjarrad K, Hall TA, et al. 2006. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. Arch Ophthalmol, 124:33-7.
52. McGwin G Jr, Owsley C, Curcio CA, et al. 2003. The association between statin use and age related maculopathy. Br J Ophthalmol, 87:1121-5.
53. McGwin G Jr, Xie A, Owsley C. 2005. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology, 112:488-94.
54. Metha AB, Vingrys AJ, Badcock DR. 1993. Calibration of a colour monitor for visual psychophysics. Beh Res Meth Instrum Comp, 25:371-83.
55. Mitchell P, Smith W, Attebo K, et al. 1995. Prevalence of age-related maculopathy in Australia. Ophthalmology, 102:1450-60.
56. [NHFA] National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. 2001. Lipid management guidelines 2001. Med J Aust, 175(Suppl):S57-S85.
57. Owsley C, Jackson G, White M, et al. 2001. Delays in rod-mediated dark adaptation in early age-related maculopathy. Ophthalmology, 108:1196-202.
58. Owsley C, Jackson GR, Cideciyan AV, et al. 2000. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci, 41:267-73.
59. Phipps JA, Guymer RH, Vingrys AJ. 2003. Loss of cone function in age-related maculopathy. Invest Ophthalmol Vis Sci, 44:2277-83.
60. Pruefer D, Scalia R, Lefer AM. 1999. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol, 19:2894-900.
61. Robman L, McNeil J, Dimitrov P, et al. 2004. Methodology of the Cardiovascular Health and Age-Related Maculopathy (CHARM) Study. Ophthalmic Epidemiol, 11:161-79.
62. Rothman K, Greenland S, 1998. Modern Epidemiology. Philadelphia, PA: Lipcott Williams and Wilkins.
63. Sackett CS, Schenning S. 2002. The age-related eye disease study: the results of the clinical trial. Insight, 27:5-7.
64. Said F, Weale R. 1959. The variation with age of the spectral transmissivity of the living human crystalline lens. Gerontologia, 3:213-31.
65. Smeeth L, Cook C, Chakravarthy U, et al. 2005. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol, 89:1171-5.
66. Smith W, Assink J, Klein R, et al. 2001. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology, 108:697-704.
67. Spaide RF, Ho-Spaide WC, Browne RW, et al. 1999. Characterization of peroxidized lipids in Bruch's membrane. Retina, 19:141-7.
68. Sunness JS, Massof RW, Johnson MA, et al. 1989. Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. Ophthalmology, 96:375-81.
69. Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol, 21:1712-9.
70. Tan JS, Mitchell P, Rochtchina E, et al. 2007. Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. Am J Ophthalmol, 143:685-7.
71. Taylor H, West S. 1988. A simple system for the clinical grading of lens opacities. Lens Res, 5:175-81.
72. Taylor HR. 2002. Fred Hollows lecture. Eye care for the community. Clin Exp Ophthalmol, 30:151-4.
73. Taylor HR, Tikellis G, Robman LD, et al. 2002. Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ, 325:11.
74. Tikellis G, Robman LD, Dimitrov P, et al. 2007. Characteristics of progression of early age-related macular degeneration: the Cardiovascular Health and Age-Related Maculopathy Study. Eye, 21:169-76.
75. van Leeuwen R, Klaver CC, Vingerling JR, et al. 2004a. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol, 137:750-2.
76. van Leeuwen R, Tomany SC, Wang JJ, et al. 2004b. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology, 111:1169-75.
77. van Leeuwen R, Vingerling JR, Hofman A, et al. 2003. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ, 326:255-6.
78. VanNewkirk M, Nanjan M, Wang J, et al. 2000. The prevalence of age-related maculopathy: the Visual Impairment Project. Ophthalmology, 107:1593-600.
79. Watts G. 2001. Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. Curr Control Trials Cardiovasc Med, 2:118-22.
80. Wilson HL, Schwartz DM, Bhatt HR, et al. 2004. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol, 137:615-24.
81. Zele A, Vingrys A. 2005. Cathode-ray-tube monitor artefacts in neurophysiology. J Neurosci Methods, 141:1-7.